文献速递神经肿瘤

程序性死亡配体1是复发性异柠檬酸脱氢酶野生型胶质母细胞瘤的负向预后标志物

Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
PubMed 文献 · Neurosurgery · 2019-01-01

本研究用组织芯片比较5种程序性死亡配体1(PD-L1)单克隆抗体,并以定量免疫组化与RNA原位杂交验证弥漫性胶质瘤中PD-L1的表达,按2016年修订版WHO分类分析其与临床结局的关系。以5%为界值,PD-L1表达与组织学定义的胶质母细胞瘤及复发性异柠檬酸脱氢酶(IDH)野生型胶质母细胞瘤的不良预后显著相关,Cox回归中仍为显著负向预后因素。

要点

  • 以5%为界值,PD-L1表达与组织学定义胶质母细胞瘤的不良预后显著相关(log-rank P < .001)。
  • 复发性IDH野生型胶质母细胞瘤中PD-L1表达与不良预后显著相关(log-rank P = .015)。
  • 作者认为该结果可能对PD-1/PD-L1阻断的未来临床试验中的患者分层有参考意义。

核心结论

  • 以5%为PD-L1表达界值可识别出临床结局更差的一部分胶质母细胞瘤,且该关联在新定义的IDH野生型分类中仍然显著。

研究设计与样本

  • 研究采用组织芯片,比较5种PD-L1单克隆抗体(n = 56),并用定量免疫组化(IHC)与RNA原位杂交(RISH)验证表达(n = 183)。
  • 按2016年修订版WHO分类分析弥漫性胶质瘤,并将癌症基因组图谱(TCGA)及已发表研究的表达数据与临床结局比较。
  • 采用多重免疫表型分析识别治疗后胶质母细胞瘤中的PD-L1阳性细胞群。

主要发现

  • 以5%为界值,PD-L1表达与组织学定义的胶质母细胞瘤不良预后显著相关(n = 125,log-rank P < .001)。
  • 以5%为界值,PD-L1表达与复发性IDH野生型胶质母细胞瘤不良预后显著相关(n = 60,log-rank P = .015)。
  • Cox回归分析中PD-L1仍为显著的负向预后因素(风险比:1.96,P = .021)。
  • TCGA数据分析显示复发性非胶质瘤CpG岛甲基化表型(G-CIMP)胶质母细胞瘤总生存期降低(n = 12,log-rank P = .023),而胶质母细胞瘤整体组未见此关联(n = 444,log-rank P = .135)。
  • PD-L1的RISH结果与IHC显著相关(P < .0001),且PD-L1见于治疗后胶质母细胞瘤增殖的血管周干细胞与免疫微环境。

关键数值与推荐

  • PD-L1表达界值为5%。
  • 组织学定义胶质母细胞瘤:n = 125,log-rank P < .001。
  • 复发性IDH野生型胶质母细胞瘤:n = 60,log-rank P = .015。
  • Cox回归:风险比1.96,P = .021。
  • TCGA复发性非G-CIMP胶质母细胞瘤:n = 12,log-rank P = .023;TCGA胶质母细胞瘤整体:n = 444,log-rank P = .135。

临床怎么用

  • 作者认为,上述发现可能对PD-1/PD-L1阻断的未来临床试验中的患者分层有参考意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Checkpoint inhibition has demonstrated clinical efficacy in a variety of solid tumors. Reports of programmed death ligand 1 (PD-L1) expression in glioblastoma are highly variable (ranging from 6% to 88%) and its role as a prognostic marker has yielded conflicting results. OBJECTIVE: To validate the prevalence and prognostic role of PD-L1 expression in a large cohort of diffuse gliomas according to the 2016 revised WHO classification. METHODS: Using tissue microarrays, we compared 5 PD-L1 monoclonal antibodies (n = 56) and validated expression (n = 183) using quantitative immunohistochemistry (IHC) and RNA in situ hybridization (RISH). Expression data from The Cancer Genome Atlas (TCGA) and published studies were compared with clinical outcome. Multiplexed immunophenotyping was used to identify PD-L1+ cell populations in post-treatment glioblastoma. RESULTS: Using a 5% cut-off, PD-L1 expression was significantly associated with a poor prognosis in both histologically defined (n = 125, log-rank P < .001) and recurrent isocitrate dehydrogenase (IDH)-wildtype glioblastoma (n = 60, log-rank P = .015). PD-L1 remained a significant negative prognosticator in Cox regression analysis (hazard ratio: 1.96, P = .021). Analysis of TCGA data confirmed decreased overall survival in recurrent non-glioma CpG island methylator phenotype (G-CIMP) glioblastoma (n = 12, log-rank P = .023), but not in glioblastoma as a group (n = 444, log-rank P = .135). PD-L1 RISH showed a significant correlation with IHC (P < .0001). PD-L1 was observed in the proliferating perivascular stem cell and immune niche of post-treatment glioblastoma. CONCLUSION: A 5% PD-L1 expression cut-off identified a subset of glioblastoma that is associated with a worse clinical outcome. This association remained significant within the newly defined IDH-wildtype classification. These findings could have implications for patient stratification in future clinical trials of PD-1/PD-L1 blockade.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Pratt D, Dominah G, Lobel G, et al. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma. Neurosurgery. 2019. PMID: 30011045. doi:10.1093/neuros/nyy268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。